Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An eventful year — including panel meetings, approvals and a refusal to file a new drug application — has sharpened the focus around the FDA's requirements for accelerated approval of anticancer drugs.